Effects of Whole-Body HIIT and Moderate Continuous Exercise on Immune Function (WBHIIT-IMM)

May 23, 2026 updated by: Melih Calişir, Bitlis Eren University

Effects of Whole-Body High-Intensity Interval Training and Moderate-Intensity Continuous Exercise on Immune Function in Recreationally Active Men

This randomized controlled trial aimed to investigate the effects of a 12-week Whole-Body High-Intensity Interval Training (WB-HIIT) program compared with Moderate-Intensity Continuous Training (MICT) on immune function in recreationally active young adults. Participants were randomly assigned to either WB-HIIT or MICT groups. Immune-related biomarkers and performance outcomes were assessed before and after the intervention. The study sought to determine whether different exercise modalities produce distinct adaptations in immune function.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study was designed as a two-arm, parallel-group, randomized controlled trial. A total of 20 recreationally active male participants were randomly assigned to either the Whole Body High-Intensity Interval Training (WB-HIIT) group or the Moderate-Intensity Continuous Training (MICT) group. The intervention lasted 12 weeks and involved supervised training sessions multiple times a week.

The WB-HIIT protocol consisted of repeated high-intensity whole-body exercises performed at near-maximum effort with intermittent rest periods, while the MICT group performed moderate-intensity continuous aerobic exercise. Immune function was assessed through selected hematological and biochemical markers collected at baseline and post-intervention. In addition, physical performance variables were evaluated to examine secondary adaptations to different exercise modalities. The primary aim of the study was to compare the effects of WB-HIIT and MICT on immune system responses, while secondary outcomes included changes in exercise performance. This study provides insights into how different training intensities affect immune regulation in individuals who are active in their leisure time.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
20

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Merkez
      • Bitlis, Merkez, Turkey (Türkiye), 13100
        • Bitlis Eren University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

Healthy male adults Aged 18-25 years Not engaged in regular structured exercise training (>3 sessions/week) VO₂max within normal healthy range Willingness to participate and provide informed consent No acute or chronic inflammatory, metabolic, or cardiovascular disease

Exclusion Criteria:

Female participants (not included in study design) Smoking or alcohol abuse Use of anti-inflammatory or immunomodulatory drugs Participation in regular high-intensity training programs Musculoskeletal limitations preventing exercise testing or training Acute infection within last 2 weeks Chronic metabolic, cardiovascular, or autoimmune diseases

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Whole-Body HIIT
Participants will perform Whole-Body High-Intensity Interval Training (WB-HIIT) protocol.
Behavioral: Whole-Body High-Intensity Interval Training (WB-HIIT)
Whole-body high-intensity interval training protocol performed under supervision.
Active Comparator: MICT
Participants will perform Moderate-Intensity Continuous Training (MICT) protocol.
Behavioral: Moderate-Intensity Continuous Training (MICT)
Moderate-intensity continuous training protocol performed under supervision.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Peripheral immune cell counts
Time Frame: Baseline and 8 weeks (post-intervention)
Changes in peripheral blood leukocyte, lymphocyte subsets, neutrophil, and monocyte counts from baseline to post-intervention (8 weeks).
Baseline and 8 weeks (post-intervention)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Inflammatory cytokine levels
Time Frame: Baseline and 8 weeks (post-intervention)
Changes in serum IL-6, TNF-α, and CRP levels from baseline to post-intervention (8 weeks).
Baseline and 8 weeks (post-intervention)
Immunoglobulin levels
Time Frame: Baseline and 8 weeks (post-intervention)
Changes in serum immunoglobulin (IgA, IgG, IgM) concentrations from baseline to post-intervention (8 weeks).
Baseline and 8 weeks (post-intervention)
Cortisol levels
Time Frame: Baseline and 8 weeks (post-intervention)
Changes in serum cortisol levels as a marker of exercise-induced stress response from baseline to post-intervention (8 weeks).
Baseline and 8 weeks (post-intervention)
Maximal oxygen uptake (VO₂max)
Time Frame: Baseline and 8 weeks (post-intervention)
Changes in VO₂max measured by cardiopulmonary exercise testing from baseline to post-intervention.
Baseline and 8 weeks (post-intervention)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Bitlis Eren University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Melih Çalışır, PhD, Bitlis Eren Üniversitesi University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 30, 2020

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 30, 2020

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 30, 2020

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 16, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 23, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 1, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 1, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 23, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2020-189

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared due to participant privacy and confidentiality concerns.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Exercise Physiology

Clinical Trials on Whole-Body High-Intensity Interval Training (WB-HIIT)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings